IL6 and breast carcinoma: For instance, it has been demonstrated that IL-6, secreted by adipocytes, is able to induce epithelial–mesenchymal transition [88], enrichment of cancer stem cells, and resistance to PI3K inhibitors [89] via STAT3 activation in ER-expressing MCF-7 breast cancer cells.